A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the breast.

- Measurable or evaluable locally advanced or metastatic disease.

- Age ≥18 years.

- Disease progression during or after treatment with a bevacizumab-containing regimen
in the adjuvant or first-line metastatic setting.

- Patients must have discontinued chemotherapy at least 3 weeks prior to randomization.

- No more than one prior chemotherapy regimen for locally advanced or metastatic
disease.

- Prior hormonal therapy allowed provided it has been discontinued prior to
randomization.

- Prior radiation therapy is allowed but must be completed at least 3 weeks prior to
randomization. Previously radiated area(s) must not be the only site of disease.

- ECOG Performance Status of 0 or 1.

- Adequate bone marrow, liver, and renal function

- Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to randomization, and must agree to use adequate contraception
prior to study entry, for the duration of study participation and 28 days after the
last study drug dosing.

- Patients must be able and willing to sign a written informed consent.

- Patients must be able to swallow and retain oral medication.

Exclusion Criteria:

- Patients with breast cancer over-expressing human epidermal growth factor receptor 2
(HER-2) (gene amplification by FISH or 3+ over-expression by immunohistochemistry).
Patients with unknown HER-2 status are not eligible.

- Patients with active brain metastases.

- Major surgery, open biopsy, or significant traumatic injury within 4 weeks of
randomization.

- Prior use of gemcitabine/capecitabine or sorafenib.

- Evidence or history of bleeding diathesis or coagulopathy.

- Serious, non-healing wound, ulcer, or bone fracture.

- Substance abuse, or medical, psychological, or social condition that may interfere
with the patient's participation in the study or evaluation of the study results.

- Use of cytochrome P450 enzyme-inducing anti-epileptic drugs is not allowed.

- Clinically significant cardiac disease

- Uncontrolled hypertension

- Thrombolic, embolic, venous, or arterial events such as a cerebrovascular accident
including transient ischemic attacks within the past 6 months.

- Pulmonary hemorrhage/bleeding event > NCI-CTCAE Grade 2 within 4 weeks of
randomization.

- Any other hemorrhage/bleeding event ≥ NCI-CTCAE Grade 3 within 4 weeks of
randomization.

- Active clinically serious infection > NCI-CTCAE Grade 2.

- Known HIV infection or chronic hepatitis B or C (the safety and effectiveness of
sorafenib in this patient population have not been studied).

- Previous or concurrent cancer that is distinct in primary site or histology from
breast cancer EXCEPT cervical cancer in-situ, treated basal cell carcinoma,
superficial bladder tumors [Ta and Tis] or any cancer curatively treated > 5 years
prior to randomization.

- Known or suspected allergy to sorafenib or gemcitabine/capecitabine.

- Prior or concurrent use of St. John's Wort or rifampin (rifampicin) within 3 weeks of
randomization.

- Concurrent anti-cancer therapy other than gemcitabine/capecitabine and
sorafenib/placebo.

- Prior treatment with any agent that targets VEGF or VEGFR (licensed or
investigational), except bevacizumab.

- Women who are pregnant or breast-feeding.

- Use of any investigational drug within 30 days or 5 half-lives, whichever is longer,
preceding randomization.

- Inability to comply with protocol and/or not willing or not available for follow-up
assessments.

- Any condition which in the investigator's opinion makes the patient unsuitable for
the study participation.